phasize the role of mucin-secreting tissues in the histopathogenesis of the disease (6). The mucins of CF patients are relatively normal except for their longer carbohydrate chains and higher sulfation as compared to controls (7-13), but the reason for their increased viscosity is unknown. The pathology of cystic fibrosis includes blockage of vital passages by viscid mucus secretions, resulting in the patients' premature deaths (4, 5) .
Several investigators (14-16) have recently described abnormally high mucin-associated antigen levels in the serum of C F patients. Our initial impression was that serum mucin-associated antigens originated from C F patients' damaged pancreatic ductal epithelium (14) . Indeed, inspissated mucus plugs in the pancreatic ductal system of CF patients are an almost constant histopathologic feature of the disease even in the neonatal period (4) (5) (6) (17) (18) (19) . Crossley et al. (20) thought pancreatic ductal obstruction caused "back-leakage" (20) of acinar digestive enzymes across the epithelium of ductal lumens and eventually into the plasma of about 90% of CF neonates (21) . Radioimmunoassays for the detection of increased concentrations of pancreatic enzymes such as trypsinogen in the blood of newborns are now widely used as an experimental means to screen neonates for CF (20) (21) (22) (23) (24) (25) (26) . We thought mucins from CF patients' pancreata might enter their circulatory system by the same pathologic route proposed for pancreatic enzymes.
Unlike the pancreatic enzymes in CF patients' sera (23, (27) (28) (29) , however, elevated serum mucin-associated antigen levels persisted among several adult C F patients (14) . An elevated serum mucin-associated antigen level was reported in one adult CF without clinical evidence of pancreatic dysfunction (14) . Furthermore, some infants lacking pancreatic enzyme elevation in their serum have elevated levels of mucin (16) . Because measurements of serum mucin-associated antigen levels have been used to detect and monitor patients with pancreatic adenocarcinoma and other gastrointestinal cancers (30) (31) (32) (33) , serum mucin-associated antigen levels might also reflect the clinical status of CF patients. In the present study, serum mucin-associated antigen levels were measured in specimens from 89 C F patients and from seven non-CF lung disease patients in order to determine if serum levels related to age and clinical status.
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FRATES ET AL. and 3) Non CF Lung Disease Group: 7 non CF patients with bronchiectasis from whom one blood sample each was obtained.
The blood samples from the patients comprising the CF serial sample group came from a frozen serum bank at Children's Hospital National Medical Center in Washington, DC. Patients were routinely asked to give blood during regular outpatient clinic visits. At the time of the study, the number of blood samples from an individual CF patient ranged from 1-9. We decided to study all patients in the bank for whom a minimum of five repeated samples were available. This number maximized the number of both patients and samples available. A total of 24 patients had contributed five or more blood samples. Of these, three patients were deleted because they were Le (a-b-), and one additional patient was deleted because a chest roentgenogram was missing. This left 20 patients for study. At the time the patients were chosen, mucin-associated antigen levels had not been calculated from their blood samples. Of the 100 specimens from these 20 patients, only three were drawn within 1 month of hospitalization. Blood samples were collected during the period [1981] [1982] [1983] [1984] [1985] [1986] .
Single blood samples were drawn from 69 CF patients at the National Institutes of Health and Children's Hospital National Medical Center Washington, DC. All of the CF patients at NIH (30) during 198 1-1 986 volunteered to have their blood used or drawn for the study. The remaining blood samples come from the frozen serum bank taken from outpatients at Children's Hospital who volunteered to give blood during their routine clinic visits. Some of the NIH patients were about to be hospitalized. Le (a-b-) patients were deleted from the sample. These specimens were also obtained from 198 1-1 986.
The serum and saliva specimens and brief clinical histories from seven patients with non-CF lung disease were kindly provided by Dr. Michael Knowles, University of North Carolina. The basis of his selection was non-CF patients who had bronchiectasis; six of the seven had also grown Pseudomonas aeruginosa from their sputa. Specimens were obtained under protocols approved by the Human Subjects Committees of the different institutions.
Patient characteristics. All CF patients had repeated sweat chloride concentrations of more than 60 mEq/liter using the method of Gibson and Cooke (34) and had clinical findings appropriate for CF. Patients ranged in age from 1 day to 41 y, with an average age of 14 y, 6 months. Forty-one females and 48 males were included in the study. Among the nine male and 12 female CF patients who donated serial samples, ages ranged from 2 months to 17 y 3 months, with an average age of 6y, 6 months.
The characteristics and results from seven non-CF control patients are given in detail in at -20°C within a few h of collection.
Patients were typed for their Lewis blood group. Crude saliva preparations were typed by means of an RIA as described elsewhere (35) using monoclonal antibodies to the Lewis blood group antigens, Lea and Leb, produced by the hybridoma cell lines 15 1-6-A7-9 and 143-2-A6-11, respectively (American Type Culture Collection HB8324 and HB8325, Rockville, MD). A few patients were typed by the usual red blood cell hemagglutination method. Only those patients belonging to the Le (a-b+) or Le (a+b-) blood groups were included in the study.
Scoring. A physician unaware of the CF patients' serum mucin-associated antigen measurements retrospectivly reviewed the charts and chest roentgenograms of the 20 patients in the CF serial sample group. For each outpatient visit when a serum specimen was obtained, the physician assigned each patient a Shwachman-Kulczycki clinical score (as modified by Doershuk, et al. (36) and a Brasfield chest roentgenogram score (37) . Mucin assay. Serum specimens were assayed for mucin-associated antigen levels using the "CA 19-9 RIA kit" (Centocor, Malvern, PA). Monoclonal antibody 19-9 detects sialyl Lea blood group antigen derivative on mucins in human serum (38, 39) (see "Discussion"). Results are given in U/ml based on standards supplied by the manufacturer. The relative expression of sialyl Lea antigen on mucins varies among individuals and binding of the 19-9 monoclonal antibody is, therefore, not a measure of absolute mucin concentrations.
Characterization of the serum mucin-associated antigen from sera of CF patients. Three types of experiments were performed to characterize the antigen detected by monoclonal antibody 19-9 in the sera of CF patients. The experiments included gel filtration chromatography on sera on an Sephacryl S-400 column (39) with further purification and analysis of the antigen by density gradient ultracentrifugation (39) (40) (41) . Thin-layer chromatography with autoradiography of total lipid extracts from a patient's serum and red blood cells was also completed (38, 39) . Details of these experiments will be presented in a future publication.
Statistical analyses of serially sampled patients. Five serum
samples were selected from 20 C F patients who had previously donated multiple blood samples. Patients had blood samples, Brasfield roentgenogram scores and Shwachman-Kulczycki clinical scores for each clinic visit. Braesfield and ShwachmanKulczycki clinical scores were treated as dependent variables in the subsequent analyses. For each dependent variable, the data were subjected to a one-way ANCOVA in which "time points" (the outpatient CF clinic visits for which scores were assigned) was treated as the within-subjects factor and serum mucinassociated antigen levels as a covariate that changed across the within-subjects factor (42, 43) . In this way, two ANCOVA were conducted: one using Brasfield roentgenogram scores as the dependent variable and the other using Shwachman-Kulczycki clinical scores as the dependent variable. The time points factor was included in the analyses to account for any increase in scores due to the passage of time. Although time points was a continous measure, its values were categorized because the intervals between clinical visits varied for each patient. The covariate, serum mucin-associated antigen levels, was not introduced into the analyses for the purpose of statistical control, but rather to assess the statistical significance of its contributions to ShwachmanKulczycki scores and Brasfield scores. Thus, unlike the typical interpretation of an ANCOVA, the covariate was the variable of interest, whereas the statistical significance of the main effect was of subsidiary importance.
RESULTS

Results of serum mucin-associated antigen characterization experiments.
Gel chromatography experiments demonstrated elution of the serum mucin antigen as determined by solid-phase RIA (38, 39) in the void volume of a Sephacryl S-400 column (39) . These antigen-positive fractions were then pooled and further purified by density gradient ultracentrifugation (39) (40) (41) . These experiments demonstrated that the antigen has a mol wt > 2 x lo6 with a density of 1.41 g/ml in guanidine and cesium chloride. Immunostaining with monoclonal antibody 19-9 of total lipid extracts from a CF patient's sera and red blood cells did not detect any glycolipid antigen reactive with the antibody, whereas sialyl Lea was stained by the antibody (38, 39) . Taken together, the results of these experiments demonstrate that the serum antigen is of high molecular weight with a density greater than that of a typical protein or glycoprotein (1.2 to 1.3 g/ml) (39) but less than that of a proteoglycan (>1.5 g/ml) (44, 45) , and that the antigen is not a lipid. Thus, the antigen detected by monoclonal antibody 19-9 in the serum of many C F patients is probably on a mucin.
Results of analyses of CF serial sample group. The means of the variables used in the analyses of covariance are provided in Table 2 . The first consideration is the analysis in which the Brasfield scores were treated as the dependent variable. As would be expected, Brasfield scores decreased across time points, giving rise to a main effect of time points, F (4, 75) = 9.54, p < 0.001. Although the above analyses involved two different dependent variables that assessed the severity of CF, the conclusions are the same: serum mucin-associated antigen levels accounted for a significant proportion of the variance of the measure of clinical scores above that accounted for by the passage of time.
Data from representative patient from the group of the 10 CF patients whose clinical scores never changed more than 10 points between clinic visits are presented in Figure 1 D. The mean serum mucin-associated antigen levels for each of these 10 stable patients ranged from 20-270 U/ml but generally remained constant. One patient was an exception with a constant clinical score of 95 points over 4 years who had a 180% increase above her mean mucin-associated antigen level from one visit to the next. Eleven C F patients' clinical scores changed by more than 10 points between clinic visits. Their mean serum mucin levels ranged from 15 to 306 U/ml. The data from three patients from this group are presented in Figure IA , B, and C. Unfortunately, there were not enough data to permit statistical analysis of the relation between individual CF patient's clinical scores and the respective serum mucin-associated antigen levels, but an inverse relation seems to exist on inspection of the available data ( Results of analyses of CF single sample group. There was a relation between age and serum mucin levels (Fig. 2) . For all 89 CF patients, mucin-associated antigen levels were positively correlated with age, r(88) = + 0.215, p < 0.025 (Fig. 2, line b) . For those 69 CF patients 22 years of age or younger, the correlation was also significant, r(68), = + 0.426, p < 0.005 (Fig. 2, line a) .
Elevated serum mucin-associated antigen levels of the 89 patients were not related to respiratory tract infection with P. aeruginosa. For the 12 CF patients who never had pseudomonas grown from repeated sputum cultures, the mean U/ml ( f 1 SD) was 194 f 359. For the other 77 CF patients, the mean was 140 + 149. The difference between the groups was not significant, t(87) = 0.5 14, p > 0.05. For the six nonCF patients with bronchiectasis and pulmonary Pseudomonas colonization or infection, the average serum mucin-associated antigen level was 20 f 18 U/ml of serum; their mean serum mucin level was significantly lower than the mean serum mucin-associated antigen level of the Pseudomonas colonized or infected CF group, t(81) = 1.96, p = 0.053. There was no difference between mean serum mucin-associated antigen levels of the six non-CF patients and the pseudomonas-free CF patients, t(16) = 0.53, p > 0.05.
The serum mucin-associated sialyl Lea antigen levels for 51 CF patients with known Lewis blood types are provided in Table  3 . The six Le (a+b-) patients were evenly divided between the sexes. Of the 45 Le (a-b+) patients, there were 24 females and 21 males. Higher levels are generally found in Le (a+b-) patients than in Le (a-b+) patients, whereas Le (a-b-) patients do not make detectable antigen. Fig. 2 . Correlation of serum mucin-associated antigen levels (Sialyl Lea antigen) levels with CF patients' ages. Serum mucin-associated antigen levels determined using monoclonal antibody 19-9 are presented as a function of age for 89 patients belonging to the Le (a+b-) or Le (a-b+) blood groups. Regression line a is for patients 22 y old or younger, and line b is for the entire sample. The ANCOVA show that serum mucin-associated antigen levels of CF patients were related to their clinical and chest roentgenographic scores. The proportion of variance explained by the Shwachman-Kulczycki scores was higher than that by the Brasfield chest roentgenographic scores. That the relation between serum mucin-associated antigen levels and illness was found using these two different scales attests to the reliability of the finding. However, this difference in the proportion of variance between the two scoring systems may or may not be meaningful because of the differences in these two scales.
PATIENTS' AGE IN YEARS
The Shwachman-Kulczycki system was modified by Doershuk et al. (36) to enhance its detail. This system awards 25 points in each of four categories: interval symptomatic history, pulmonary physical findings and the nature of the CF patient's cough, growth pattern, and the chest roentgenogram appearance. A perfect score of 100 points means a normal asymptomatic individual. The system is subjective, but it has recently been demonstrated to have "acceptable" interobserver variance (46) . The score has not been tested for prognostic value. It is widely used, however, because it does not require pulmonary function test data as does the Taussig-Kattwinkel prognostic scoring system for CF patients (47) . Many of the 20 patients in our serial blood sample group were too young for breathing tests when they began participating in the study. By contrast, the 25-point chest roentgenogram scoring system devised by Brasfield et al. (37, 48) correlates sinnificantlv with vulmonarv function tests. and was successfullv tested for ;eprod;cibility b;l and between observers. That thk scores from this carefully validated system of evaluation correlated so well with the patients' serum mucin-associated antigen levels is particularly encouraging. The ShwachmanKulczycki score's closer association with serum mucin-associated antigen levels may have been due to its inclusion of other aspects of the patient's condition, such as growth pattern, which were omitted from the Brasfield evaluation. Because the time points factor was included in both of the analyses, the relation between serum mucin-associated antigen levels and the two dependent variables (Shwachman-Kulczycki and Brasfield scores) could not be attributed to the progression of the disease over time.
Serum mucin-associated antigen levels increased with the age of CF patients (Fig. 2) . Interestingly, the correlation of serum mucin levels with age was greater for those patients 22 y of age or younger (+ 0.426) than for older patients (+ 0.215). The median survival age for CF patients in the United States is about 26 y (49). The association of lower serum mucin-associated antigen levels with the longer-lived group suggests that mucin levels may be of prognostic value in the long-term evaluation of CF patients.
To be a clinically useful test, serum mucin-associated antigen levels must reflect changes in the individual patient's clinical situation. Figure 1 illustrates that serum mucin-associated antigen levels reflected the clinical courses of four patients. The small number of serial serum specimens available from each patient precluded statistical analyses of individual patients. For many of the CF patients tested so far, however, mucin-associated antigen levels were inversely related to their individual condition.
The assay using monoclonal antibody 19-9 does not measure absolute levels of mucin and, therefore, levels among various patients cannot be compared. This results in part from phenotypic variation of Lewis blood group antigen expression. Monoclonal antibody 19-9 recognizes the sialyl Lea antigen, whose structure is NeuAca 2-3 GalP 1-3[Fucal-4]GlcNAc/3 1-3 Gal. . . (38) . The antigen is associated with mucins in the serum of cancer patient (39) and of CF patients (Roberts D, Rose M, Wang W, Chernick M, Frates D, manuscript in preparation). CF patients who belong to the Le (a-b-) blood group were excluded from the statistical analyses. These individuals, who comprise about 7% of the general population, do not have a Le gene that specifies the glycosyltransferase responsible for the synthesis of the Fucal-4GlcNAc linliage (50) , and that is required for the synthesis of the sialyl Lea antigen (5 1). All Le (a+b-) and most Le (a-b+) individuals can make the sialyl Lea antigen, but some Le (a++) individuals do not make detectable levels probably because of enzyme competition for precursors (35, 47, 50, 5 1) .
The present results are consistent with these findings as shown in Table 3 . The six Le (a+b-) CF patients had average mucinassociated antigen levels four times higher than those of the 45 Le (a-b+) cystic fibrosis patients. Those patients who were Le (a-b-) did not have detectable sialyl Lea antigen in their serum. Use of monoclonal antibody 19-9 underestimates serum mucin levels for many patients who are not Le (a+b-). Antibodies directed against serum mucin-associated antigens other than the sialyl Lea carbohydrate group may be used with those patients genetically unable to make detectable levels of sialyl Lea antigen (52) .
The results presented here are from blood samples drawn months apart and do not address the issue of how promptly serum mucin-associated antigen levels rise or fall in response to changes in the patients. The concentration of mucin-associated antigens in the sera of cystic fibrosis patients depends on the relative rates for their entry into and clearance from the bloodstream. These rates and the site of clearance are unknown.
Because sialyl Lea antigen is normally present on mucins in the lung (53) as well as the pancreas (54), salivary glands (35, 54) , milk (55) , seminal fluid (56) , and gut (54), serum mucinassociated antigen could arise from several sources. The pancreas is not the exclusive source of mucin-associated antigens in serum because high serum mucin-associated antigen levels do not depend on pancreatic function. Four CF patients who had insulindependent diabetes, a condition which includes almost complete pancreatic destruction including mucin-secreting ductal epithelia (57) had elevated serum mucin-associated antigen levels. The negative correlation between mucin-associated antigen levels and Brasfield scores suggests that the lung is a significant source of the antigen in serum. Results with two patients also suggest that the lung contributes to serum mucin-associated antigen levels. Both patients had sudden increases in their serum mucin-associated antigen levels, one seven times and the other about 70 times (Fig. I B) their respective baseline values. Concurrent with these increases were increased respiratory symptoms and worsened chest examination findings. One patient had a collapsed right middle lobe seen on chest roentgenogram at the time of her serum mucin-associated antigen spike. The other patient had a history of right upper lobe atelectasis and auscultatory dullness of that area of her chest, but no roentgenogram was taken on that visit. Both patients serum mucin-associated antigen levels returned to theirprevious positions with resolution of symptoms, and the one patient's chest roentgenogram showed expansion of the right middle atelectatic lobe. We suspect that other organ sources than the lung may also be important.
The measurement of serum mucin-associated antigen levels may be a promising way of monitoring the illness of some CF patients. Based on measurements of serum mucin levels from more than 2000 normal donors (30, 32) , 95% of the normal population have serum mucin levels less than 20 Ujml and 99.5% have serum mucin levels less than 37 U/ml. In contrast, only 12 of the 89 Lewis-positive CF patients (13%) had serum mucin levels less than 20 U/ml and 21 (23%) had less than 37 50% of patients who have gastrointestinal carcinomas, diseases unlikely to be confused with CF.
Serum mucin-associated antigen levels seem to be independent of tracheobronchial flora in CF patients, as there was no difference between those CF patients who had P. aeruginosa grown from their repeated sputa cultures and those CF patients whose cultures were consistently negative for this organism. Furthermore, the six nonCF lung disease control patients who had bronchiectasis and whose lungs were exposed to proteases of P. aeruginosa and other inflammatory products had a lower mean serum mucin-associated antigen level than did CF patients with Pseudomonas in their lungs ( p = 0.053), suggesting that some other variable(s) than the presence of P. aeruginosa alone was responsible for high serum mucin-associated antigen levels. This finding is important because other biochemical markers of pulmonary injury, such as elastase and other enzymes (58, 59 ) and circulating immune complexes (60) (61) (62) (63) are related to lung infections with Pseudomonas.
Unlike the available clinical scoring systems, measurements of serum mucin-associated antigens are objective and do not require physicians' time, pulmonary function tests, or x-ray exposure. Although there are other biochemical tests which reflect CF patients' clinical statuses and correlate with poor lung function and mortality rates [e.g. serum IgG (62) and immune complexes (60, 61) ], there is no information on the ready reversibility of serum IgG levels from one clinic visit to the next as is seen with serum mucin levels. Circulating immune complexes, while they are clearly associated with sicker patients, cannot be used for short-term prognosis (63) . Perhaps serum mucin-associated antigen level determinations will eventually be useful in patient evaluation if the many present problems concerned with their use can be resolved.
We conclude that the antigen detected by monoclonal antibody 19-9 in high levels in the serum of many CF patients is the sialyl Lea carbohydrate on what probably are mucin molecules. Serum mucin-associated antigen levels depend on CF patients' ages and clinical statuses. Serum mucin-associated antigen level changes in CF patients probably reflect pulmonary mucosal damage, and are not closely related to the presence of P. aeruginosa in patients' respiratory tracts. U/ml. Only 2% of 664 patients who had many different acute with nonmalignant liver disease had mucin levels <40 U/ml 
